AIMS: The aim of the pilot SECRITT trial was to evaluate the safety and feasibility of sealing the high risk IVUS and optical coherence tomography-derived thin cap fibroatheroma (TCFA), with a dedicated nitinol self-expanding vShield device. METHODS AND RESULTS: After screening with angiography, fractional flow reserve (FFR), intravascular ultrasound virtual histology (IVUS-VH) and optical coherence tomography (OCT), 23 patients met enrolment criteria (presence of non-obstructive VH-derived TCFA lesion with thin cap on OCT) and were randomised to vShield (n=13) versusmedical therapy (n=10). In the shielded group, baseline percent diameter stenosis was 33.2±13.5%, FFR was 0.93±0.06. At six-month follow-up in shielded patients percent diameter stenosis further decreased to 18.7±16.9% and FFR remained the same 0.93±0.05. Average late loss was 0.24±0.13 mm. Average baseline fibrous cap thickness was 48±12 µm. After shield placement at six-month follow-up neo-cap formation was observed with average cap thickness of 201±168 µm. There were no dissections after shield placement and no plaque ruptures. In addition, mean stent area of 8.76±2.16 mm2 increased to 9.45±2.30 mm2, that is by 9% at six-month follow-up. The number of malapposed struts decreased from 10.7% to 7.6% and the number of uncovered struts at six months was 8.1%. There were no device-related major adverse cardiovascular events (MACE) events at six-month follow-up. CONCLUSIONS: High risk plaque passivation and sealing with a vShield self-expanding nitinol device appears feasible and safe. A long-term larger randomised study with streamlined screening criteria is needed to evaluate the efficacy of this approach over medical therapy.
RCT Entities:
AIMS: The aim of the pilot SECRITT trial was to evaluate the safety and feasibility of sealing the high risk IVUS and optical coherence tomography-derived thin cap fibroatheroma (TCFA), with a dedicated nitinol self-expanding vShield device. METHODS AND RESULTS: After screening with angiography, fractional flow reserve (FFR), intravascular ultrasound virtual histology (IVUS-VH) and optical coherence tomography (OCT), 23 patients met enrolment criteria (presence of non-obstructive VH-derived TCFA lesion with thin cap on OCT) and were randomised to vShield (n=13) versus medical therapy (n=10). In the shielded group, baseline percent diameter stenosis was 33.2±13.5%, FFR was 0.93±0.06. At six-month follow-up in shielded patients percent diameter stenosis further decreased to 18.7±16.9% and FFR remained the same 0.93±0.05. Average late loss was 0.24±0.13 mm. Average baseline fibrous cap thickness was 48±12 µm. After shield placement at six-month follow-up neo-cap formation was observed with average cap thickness of 201±168 µm. There were no dissections after shield placement and no plaque ruptures. In addition, mean stent area of 8.76±2.16 mm2 increased to 9.45±2.30 mm2, that is by 9% at six-month follow-up. The number of malapposed struts decreased from 10.7% to 7.6% and the number of uncovered struts at six months was 8.1%. There were no device-related major adverse cardiovascular events (MACE) events at six-month follow-up. CONCLUSIONS: High risk plaque passivation and sealing with a vShield self-expanding nitinol device appears feasible and safe. A long-term larger randomised study with streamlined screening criteria is needed to evaluate the efficacy of this approach over medical therapy.
Authors: Christos V Bourantas; Hector M Garcia-Garcia; Carlos A M Campos; Yao-Jun Zhang; Takashi Muramatsu; Marie-Angèle Morel; Shimpei Nakatani; Xingyu Gao; Yun-Kyeong Cho; Yuki Isibashi; Frank J H Gijsen; Yoshinobu Onuma; Patrick W Serruys Journal: Int J Cardiovasc Imaging Date: 2014-01-24 Impact factor: 2.357
Authors: H A Hildebrandt; P Kahlert; T F M Konorza; B Plicht; T Baars; P Kleinbongard; G Heusch; R Erbel Journal: Herz Date: 2013-05-08 Impact factor: 1.443
Authors: Hector M Garcia-Garcia; Ik-Kyung Jang; Patrick W Serruys; Jason C Kovacic; Jagat Narula; Zahi A Fayad Journal: Circ Res Date: 2014-06-06 Impact factor: 17.367
Authors: Marcella A Calfon Press; Georgios Mallas; Amir Rosenthal; Tetsuya Hara; Adam Mauskapf; R Nika Nudelman; Alexander Sheehy; Igor V Polyakov; Frank Kolodgie; Renu Virmani; J Luis Guerrero; Vasilis Ntziachristos; Farouc A Jaffer Journal: Eur Heart J Cardiovasc Imaging Date: 2017-05-01 Impact factor: 6.875
Authors: Nay Min Htun; Yung Chih Chen; Bock Lim; Tara Schiller; Ghassan J Maghzal; Alex L Huang; Kirstin D Elgass; Jennifer Rivera; Hans G Schneider; Bayden R Wood; Roland Stocker; Karlheinz Peter Journal: Nat Commun Date: 2017-07-13 Impact factor: 14.919